Following ASCO 2023, experts in oncology review recent data updates from KEYNOTE-789 on chemotherapy with or without pembrolizumab for TKI-resistant nonsquamous NSCLC.
CheckMate-77T Update: Nivolumab-Based Regimen Improves EFS in NSCLC
In the phase 3 CheckMate-77T trial, a neoadjuvant and adjuvant treatment strategy including nivolumab and chemotherapy improved survival in resectable stage IIA to IIIB non–small cell lung cancer.
Read More
Strategies for Neoadjuvant NSCLC Treatment
In season 4, episode 13 of Targeted Talks, Benny Weskler, MBA, MD, FACS, FACCP, discusses neoadjuvant therapy for patients with non–small cell lung cancer.
Listen
Choosing Appropriate Patients for Dual Immunotherapy/Chemotherapy in NSCLC
During a Targeted Oncology™ Case-Based Roundtable™ event, Sandip P. Patel, MD, discussed which patients with non–small cell lung cancer should receive immunotherapy-containing regimens. This is the second of 2 articles based on this event.
Individualizing Immunotherapy in Non–Small Cell Lung Cancer
Community physician Jason Williams, MD, DABR, talks to academic oncologist George R. Simon, MD, FACO, FCCP, for an episode of Targeted Talks.
Atezolizumab Combo Shows Potential in Advanced NSCLC With Brain Metastases
Atezolizumab, carboplatin, and pemetrexed demonstrated efficacy and safety in patients with advanced lung cancer with untreated brain metastases.
Significant Benefit Shown with Perioperative Durvalumab/Chemo in Resectable NSCLC
According to research led by Tetsuya Mitsudomi, MD, perioperative durvalumab plus chemotherapy may be better than placebo plus chemotherapy for the treatment of resectable non–small cell lung cancer.